Biotech stocks were starved for love on Wall Street in recent years, notwithstanding revolutionary research and the launch of novel therapies for once incurable diseases.
Not anymore. The catastrophic outbreak of Covid-19 has led to a reappraisal of the sector, even if viable treatments and vaccines seem far off. Sure, biotech stocks tanked this past month, but the iShares Nasdaq Biotechnology exchange-traded fund and other industry benchmarks have been outperforming the broader market.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
What are the odds I click this and see $GILD just be honest